P-285 Therapeutic management of exocrine pancreatic cancer in elderly patients

Abstract

The overall recurrence rate was 33.9% in the CROSS group and 44.1% in the CROSS group. The patterns of recurrence were similar in both groups and distant failure predominated in this R0 cohort (23.7% in CROSS and 30.5% in PFRT). Conclusion:While the jury is still out for the best NACRT regimens for ESCC, our results suggest similar efficacy of both CROSS and PFRT regimens in those who achieved R0 resection. The pattern of recurrence was similar to those reported in the landmark CROSS study but the survival outcomes could not be reproduced in the Asian community-setting with ESCC. Further studies to optimize patient selection and treatment intensification are unmet needs for this aggressive disease.